Osteopontin in immune-mediated diseases

Journal of Dental Research

Volumn 94, Issue 12, 2015, Pages 1638-1645

  Rittling, S R ^a,b   Singh, R ^a  

^a FORSYTH INSTITUTE   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

autoimmunity; B cells; immunity; integrins; OPN; Th17

Indexed keywords

OSTEOPONTIN;

HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY BOWEL DISEASE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATORY BOWEL DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS; OSTEOPONTIN; SJOGREN'S SYNDROME;

EID: 84948441210     PISSN: 00220345     EISSN: 15440591     Source Type: Journal    
DOI: 10.1177/0022034515605270     Document Type: Article

References (60)

1. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H,. 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 287 (5454): 860-864.
2. Aziz M, Ishihara S, Mishima Y, Oshima N, Moriyama I, Yuki T, Kadowaki Y, Rumi MA, Amano Y, Kinoshita Y,. 2009. MFG-E8 attenuates intestinal inflammation in murine experimental colitis by modulating osteopontin-dependent {alpha}v{beta}3 integrin signaling. J Immunol. 182 (11): 7222-7232.
3. Boumans MJ, Houbiers JG, Verschueren P, Ishikura H, Westhovens R, Brouwer E, Rojkovich B, Kelly S, den Adel M, Isaacs J, et al. 2012. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann Rheum Dis. 71 (2): 180-185.
4. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, et al. 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 294 (5547): 1731-1735.
5. Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, Sorensen ES., 2007. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem. 282 (27): 19463-19472.
6. Christensen B, Klaning E, Nielsen MS, Andersen MH, Sørensen ES,. 2012. C-terminal modification of osteopontin inhibits interaction with the alphaVbeta3-integrin. J Biol Chem. 287 (6): 3788-3797.
7. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES,. 2005. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J. 390 (Pt 1): 285-292.
8. da Silva AP, Ellen RP, Sørensen ES, Goldberg HA, Zohar R, Sodek J,. 2009. Osteopontin attenuation of dextran sulfate sodium-induced colitis in mice. Lab Invest. 89 (10): 1169-1181.
9. da Silva AP, Pollett A, Rittling SR, Denhardt DT, Sodek J, Zohar R,. 2006. Exacerbated tissue destruction in DSS-induced acute colitis of OPN-null mice is associated with downregulation of TNF-alpha expression and non-programmed cell death. J Cell Physiol. 208 (3): 629-639.
10. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS,. 2001. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 280 (2): 460-465.
11. Frenzel DF, Borkner L, Scheurmann J, Singh K, Scharffetter-Kochanek K, Weiss JM,. 2015. Osteopontin deficiency affects imiquimod-induced psoriasis-like murine skin inflammation and lymphocyte distribution in skin, draining lymph nodes and spleen. Exp Dermatol. 24 (4): 305-307.
12. Gao B, Bataller R,. 2011. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 141 (5): 1572-1585.
13. Gazal S, Sacre K, Allanore Y, Teruel M, Goodall AH, The CARDIOGENICS Consortium, Tohma S, Alfredsson L, Okada Y, Xie G, Constantin A, et al. 2015. Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. Ann Rheum Dis. 74 (3): e19.
14. Ge X, Lu Y, Leung TM, Sorensen ES, Nieto N,. 2013. Milk osteopontin, a nutritional approach to prevent alcohol-induced liver injury. Am J Physiol Gastrointest Liver Physiol. 304 (10): G929-G939.
15. Glas J, Seiderer J, Bayrle C, Wetzke M, Fries C, Tillack C, Olszak T, Beigel F, Steib C, Friedrich M, et al. 2011. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease. PLoS One. 6 (12): e29309.
16. Gordon JN, MacDonald TT,. 2005. Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease. Gut. 54 (9): 1213-1215.
17. Han S, Zhuang H, Shumyak S, Yang L, Reeves WH,. 2015. Mechanisms of autoantibody production in systemic lupus erythematosus. Front Immunol. 6: 228.
18. Harris VK, Sadiq SA,. 2009. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther. 13 (4): 225-244.
19. Hartmann P, Seebauer CT, Schnabl B,. 2015. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res. 39 (5): 763-775.
20. Heilmann K, Hoffmann U, Witte E, Loddenkemper C, Sina C, Schreiber S, Hayford C, Holzlohner P, Wolk K, Tchatchou E, et al. 2009. Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med. 13 (6): 1162-1174.
21. Hui T, Sorensen ES, Rittling SR,. 2015. Osteopontin binding to the alpha 4 integrin requires highest affinity integrin conformation, but is independent of post-translational modifications of osteopontin. Matrix Biol. 41: 19-25.
22. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L,. 2007. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat.Immunol. 8 (1): 74-83.
23. Husain-Krautter S, Kramer JM, Li W, Guo B, Rothstein TL,. 2015. The osteopontin transgenic mouse is a new model for Sjögren's syndrome. Clin Immunol. 157 (1): 30-42.
24. Iizuka J, Katagiri Y, Tada N, Murakami M, Ikeda T, Sato M, Hirokawa K, Okada S, Hatano M, Tokuhisa T, et al. 1998. Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest. 78 (12): 1523-1533.
25. Inoue M, Shinohara ML,. 2011. Intracellular osteopontin (iOPN) and immunity. Immunol Res. 49 (1-3): 160-172.
26. Iwadate H, Kobayashi H, Kanno T, Asano T, Saito R, Sato S, Suzuki E, Watanabe H, Ohira H,. 2014. Plasma osteopontin is correlated with bone resorption markers in rheumatoid arthritis patients. Int J Rheum Dis. 17 (1): 50-56.
27. Ji HI, Lee SH, Song R, Yang HI, Lee YA, Hong SJ, Kim S, Park YB, Lee SK, Yoo MC, et al. 2014. Serum level of osteopontin as an inflammatory marker does not indicate disease activity or responsiveness to therapeutic treatments in patients with rheumatoid arthritis. Clin Rheumatol. 33 (3): 397-402.
28. Kaleta B,. 2014. Role of osteopontin in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz). 62 (6): 475-482.
29. Kazanecki CC, Uzwiak DJ, Denhardt DT,. 2007. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 102 (4): 912-924.
30. Kivisakk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL, et al. 2014. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler. 20 (4): 438-444.
31. Komine-Aizawa S, Masuda H, Mazaki T, Shiono M, Hayakawa S, Takayama T,. 2015. Plasma osteopontin predicts inflammatory bowel disease activities. Int Surg. 100 (1): 38-43.
32. Kon S, Nakayama Y, Matsumoto N, Ito K, Kanayama M, Kimura C, Kouro H, Ashitomi D, Matsuda T, Uede T,. 2014. A novel cryptic binding motif, LRSKSRSFQVSDEQY, in the C-terminal fragment of MMP-3/7-cleaved osteopontin as a novel ligand for alpha9beta1 integrin is involved in the anti-type II collagen antibody-induced arthritis. PLoS One. 9 (12): e116210.
33. Konno S, Kurokawa M, Uede T, Nishimura M, Huang SK,. 2011. Role of osteopontin, a multifunctional protein, in allergy and asthma. Clin Exp Allergy. 41 (10): 1360-1366.
34. Kourepini E, Aggelakopoulou M, Alissafi T, Paschalidis N, Simoes DC, Panoutsakopoulou V,. 2014. Osteopontin expression by CD103- dendritic cells drives intestinal inflammation. Proc Natl Acad Sci U S A. 111 (9): E856-E865.
35. Kurzbach D, Platzer G, Schwarz TC, Henen MA, Konrat R, Hinderberger D,. 2013. Cooperative unfolding of compact conformations of the intrinsically disordered protein osteopontin. Biochemistry. 52 (31): 5167-5175.
36. Lampe MA, Patarca R, Iregui MV, Cantor H,. 1991. Polyclonal B-cell activation by the Eta-1 cytokine and the development of autoimmune disease. J Immunol. 147: 2902-2906.
37. Lazaro R, Wu R, Lee S, Zhu NL, Chen CL, French SW, Xu J, Machida K, Tsukamoto H,. 2015. Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology. 61 (1): 129-140.
38. Leavenworth JW, Verbinnen B, Yin J, Huang H, Cantor H,. 2015. A p85alpha-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Nat Immunol. 16 (1): 96-106.
39. Masuda H, Takahashi Y, Asai S, Hemmi A, Takayama T,. 2005. Osteopontin expression in ulcerative colitis is distinctly different from that in Crohn's disease and diverticulitis. J Gastroenterol. 40 (4): 409-413.
40. Morales-Ibanez O, Dominguez M, Ki SH, Marcos M, Chaves JF, Nguyen-Khac E, Houchi H, Affo S, Sancho-Bru P, Altamirano J, et al. 2013. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology. 58 (5): 1742-1756.
41. Murugaiyan G, Mittal A, Weiner HL,. 2008. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol. 181 (11): 7480-7488.
42. Oz HS, Zhong J, de Villiers WJ,. 2012. Osteopontin ablation attenuates progression of colitis in TNBS model. Dig Dis Sci. 57 (6): 1554-1561.
43. Parekkadan B, Fletcher AL, Li M, Tjota MY, Bellemare-Pelletier A, Milwid JM, Lee JW, Yarmush ML, Turley SJ,. 2012. Aire controls mesenchymal stem cell-mediated suppression in chronic colitis. Mol Ther. 20 (1): 178-186.
44. Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA, Agostini H, Njike M, Barri-Ova N, Naveau S, et al. 2012. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One. 7 (4): e35612.
45. Ramaiah SK, Rittling S,. 2007. Pathophysiological role of osteopontin in hepatic inflammation, toxicity and cancer. Toxicol Sci. 103 (1): 4-13.
46. Rekvig OP,. 2015. The anti-DNA antibody: origin and impact, dogmas and controversies. Nat Rev Rheumatol. 11 (9): 530-540.
47. Rittling SR,. 2011. Osteopontin in macrophage function. Expert Rev Mol Med. 13: e15.
48. Rothstein TL, Guo B,. 2009. Receptor crosstalk: reprogramming B cell receptor signalling to an alternate pathway results in expression and secretion of the autoimmunity-associated cytokine, osteopontin. J Intern Med. 265 (6): 632-643.
49. Sage PT, Sharpe AH,. 2015. T follicular regulatory cells in the regulation of B cell responses. Trends Immunol. 36 (7): 410-418.
50. Sato T, Nakai T, Tamura N, Okamoto S, Matsuoka K, Sakuraba A, Fukushima T, Uede T, Hibi T,. 2005. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut. 54 (9): 1254-1262.
51. Seth D, Duly A, Kuo PC, McCaughan GW, Haber PS,. 2014. Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation. World J Gastroenterol. 20 (36): 13088-13104.
52. Shan M, Yuan X, Song LZ, Roberts L, Zarinkamar N, Seryshev A, Zhang Y, Hilsenbeck S, Chang SH, Dong C, et al. 2012. Cigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema. Sci Transl Med. 4 (117):117ra9.
53. Shao Z, Morser J, Leung LL,. 2014. Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-terminal fragment. J Biol Chem. 289 (39): 27146-27158.
54. Strober W, Fuss I, Mannon P,. 2007. The fundamental basis of inflammatory bowel disease. J Clin Invest. 117 (3): 514-521.
55. Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, Xie G, Philips G, Chan IS, Karaca GF, et al. 2012. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut. 61 (9): 1323-1329.
56. Tang R, Yang G, Zhang S, Wu C, Chen M,. 2014. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-alpha in inflammatory bowel disease. Inflamm Bowel Dis. 20 (11): 1950-1961.
57. Uede T,. 2011. Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol Int. 61 (5): 265-280.
58. Urtasun R, Lopategi A, George J, Leung TM, Lu Y, Wang X, Ge X, Fiel MI, Nieto N,. 2012. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin alpha(V)beta(3) engagement and PI3K/pAkt/NFkappaB signaling. Hepatology. 55 (2): 594-608.
59. Yamaguchi Y, Hanashima S, Yagi H, Takahashi Y, Sasakawa H, Kurimoto E, Iguchi T, Kon S, Uede T, Kato K,. 2010. NMR characterization of intramolecular interaction of osteopontin, an intrinsically disordered protein with cryptic integrin-binding motifs. Biochem Biophys Res Commun. 393 (3): 487-491.
60. Zhong J, Eckhardt ER, Oz HS, Bruemmer D, de Villiers WJ,. 2006. Osteopontin deficiency protects mice from Dextran sodium sulfate-induced colitis. Inflamm Bowel Dis. 12 (8): 790-796.